Kenya is among countries expected to stop the second dose of the vaccine that prevents cervical cancer, according to the World Health Organisation. The WHO Africa’s decision was announced on Wednesday at the first-ever global cervical cancer elimination forum in Colombia. Local civil society welcomed the single dose advisory and noted Kenya National Immunization Technical Advisory Group should update guidelines in Kenya. This study on single dose was done in Kenya by Kemri and it confirmed that a single dose is effective. Donors at the cervical cancer conference in Colombia also announced nearly Sh85 billion (US$600 million) in new funding to eliminate cervical cancer.
